It was a buy from neutral upgrade (2 step)
Organogenesis upgraded to Buy from Neutral at BTIG 16:59 ORGO,
Organogenesis upgraded to Buy from Neutral at BTIG 16:59 ORGO,
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
Ordinarily I'd give this a thumbsdown, but if there is a risk of a debt default, it's these type of dinosaurs you want.GLW got as high as $32.80 /// They put through a price increase today.
Corning Incorporated (GLW)
NYSE - Nasdaq Real Time Price.
31.71+0.94 (+3.05%)
As of 09:57AM EDT.
Personally, I'd go with CF though.
$66
Super large size spool of cable being delivered yesterday to a hole in the ground NYC.
That's not even the glass side of their business.
That's not even the glass side of their business.
Why Shares of Organogenesis Holdings Jumped Thursday
Key Points
Organogenesis
Market Cap
$452M
Today's Change
(12.50%) $0.43
Current Price
$3.87
Price as of May 24, 2023, 9:37 a.m. ET
The company, which specializes in wound care solutions, released first-quarter earnings.
What happened
Shares of Organogenesis Holdings (ORGO 12.50%) were up more than 30% Thursday afternoon after the healthcare company released first-quarter earnings after market close on Wednesday. The stock is up a little more than 2% so far this year.
So what
Organogenesis makes products for the advanced wound care, surgical, and sports medicine markets, using regenerative tissue-based technologies that heal chronic and acute wounds. The company reported first-quarter revenue of $107.6 million, up 10% year over year. The company operates in two segments -- advanced wound care and surgical & sports medicine -- but the former was the star for the quarter, with a 12% increase in sales over the same period last year.
In the company's earnings call, Organogenesis president and CEO Gary Gillheeney said the biggest drivers of sales in the quarter came from its PuraPly antimicrobial wound mix and non-PuraPly products, such as NuShield, a dehydrated placental allograft wound covering.
The one down note in the report was that the company lost $3 million in the quarter, or $0.02 in earnings per share (EPS), compared to a net loss of $0.9 million, or an EPS loss of $0.01 in the first quarter of 2022.
The improved revenue numbers led Organogenesis to boost its annual guidance. It says it now expects revenue between $454 million and $466 million, a rise of 2% at the midpoint, year over year. It also said it expects net income to be between $3 million and $11 million, compared to net income of $15.5 million in 2022.
Now what
The next big step for the company will be whether it can get approval from the Food and Drug Administration (FDA) for ReNu, its knee osteoarthritis therapy. The product is an injectable solution of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and extracellular matrix components. It is currently in phase 3 trials. The efficacy part of one trial is expected to finish in July, and the trial is expected to finish by the end of the year.
Key Points
Organogenesis
Market Cap
$452M
Today's Change
(12.50%) $0.43
Current Price
$3.87
Price as of May 24, 2023, 9:37 a.m. ET
The company, which specializes in wound care solutions, released first-quarter earnings.
What happened
Shares of Organogenesis Holdings (ORGO 12.50%) were up more than 30% Thursday afternoon after the healthcare company released first-quarter earnings after market close on Wednesday. The stock is up a little more than 2% so far this year.
So what
Organogenesis makes products for the advanced wound care, surgical, and sports medicine markets, using regenerative tissue-based technologies that heal chronic and acute wounds. The company reported first-quarter revenue of $107.6 million, up 10% year over year. The company operates in two segments -- advanced wound care and surgical & sports medicine -- but the former was the star for the quarter, with a 12% increase in sales over the same period last year.
In the company's earnings call, Organogenesis president and CEO Gary Gillheeney said the biggest drivers of sales in the quarter came from its PuraPly antimicrobial wound mix and non-PuraPly products, such as NuShield, a dehydrated placental allograft wound covering.
The one down note in the report was that the company lost $3 million in the quarter, or $0.02 in earnings per share (EPS), compared to a net loss of $0.9 million, or an EPS loss of $0.01 in the first quarter of 2022.
The improved revenue numbers led Organogenesis to boost its annual guidance. It says it now expects revenue between $454 million and $466 million, a rise of 2% at the midpoint, year over year. It also said it expects net income to be between $3 million and $11 million, compared to net income of $15.5 million in 2022.
Now what
The next big step for the company will be whether it can get approval from the Food and Drug Administration (FDA) for ReNu, its knee osteoarthritis therapy. The product is an injectable solution of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and extracellular matrix components. It is currently in phase 3 trials. The efficacy part of one trial is expected to finish in July, and the trial is expected to finish by the end of the year.
- Organogenesis said it expects sales to rise between 1% and 3% this year.
- The company said revenue rose by 10% year over year in the first quarter.
- Its advanced wound care segment increased sales by 12% over the same period last year.
- Don't really see what all the fuss is about. The original surgical glue these guys may own it I invested in that concept eons ago but I think a different company developed it...
The next stock that’s grinding is IMMP, bought some yesterday. Stoney it’s a biotech.
Vz are we beneath hat Fib number of yours?
Watch 4,080 <--That's the Lizard king's sweet spot. Three times he took us up from there in the past. Why this spot I have no idea.
On TV they are now saying 4,200 is very significant resistance. That's actually good.
I've been saying this for over six months... but now that we have defined it we can move past it!
S&P 500 (^GSPC)
SNP - SNP Real Time Price.
4,111.44 -34.14 (-0.82%)
As of 10:07AM EDT.
Watch 4,080 <--That's the Lizard king's sweet spot. Three times he took us up from there in the past. Why this spot I have no idea.
On TV they are now saying 4,200 is very significant resistance. That's actually good.
I've been saying this for over six months... but now that we have defined it we can move past it!
S&P 500 (^GSPC)
SNP - SNP Real Time Price.
4,111.44 -34.14 (-0.82%)
As of 10:07AM EDT.
As I have said 1000 times, 4070 and 4144 are key #'sVz are we beneath hat Fib number of yours?
Watch 4,080 <--That's the Lizard king's sweet spot. Three times he took us up from there in the past. Why this spot I have no idea.
On TV they are now saying 4,200 is very significant resistance. That's actually good.
I've been saying this for over six months... but now that we have defined it we can move past it!
S&P 500 (^GSPC)
SNP - SNP Real Time Price.
4,111.44 -34.14 (-0.82%)
As of 10:07AM EDT.
Proven a dozen times plus in the last 3 months.
VZ's golden #'s
I think the space stock with the birds already in orbit may be a safer way to get Alpha from a cheap stock.... To go all in we need some thesis...
Immutep Limited (IMMP)-They have $55 mil cash. So.....
NasdaqGM - NasdaqGM Real Time Price.
2.5900+0.2900 (+12.6087%) //
Gosh I wish I had some conviction on something.
Immutep Limited (IMMP)-They have $55 mil cash. So.....
NasdaqGM - NasdaqGM Real Time Price.
2.5900+0.2900 (+12.6087%) //
Gosh I wish I had some conviction on something.
Corning is obviously not the hot tech stock it once was-- oh the coaxil cable days...
Still pretty impressive this old tech giant is still around. It must be well run.
Profit Margin 6.66%
Operating Margin (ttm) 11.74%
Management Effectiveness
Return on Assets (ttm) 3.40%
Return on Equity (ttm) 7.84%
Income Statement
Revenue (ttm) 13.69B
Still pretty impressive this old tech giant is still around. It must be well run.
Profit Margin 6.66%
Operating Margin (ttm) 11.74%
Management Effectiveness
Return on Assets (ttm) 3.40%
Return on Equity (ttm) 7.84%
Income Statement
Revenue (ttm) 13.69B
Maybe I just suck it up and go with BFH-
Bread Financial, based in Columbus, OH, continues to benefit from data-driven marketing strategies. Solid receivables growth in Card Services should drive its top line. Acquisitions and divestitures will aid the company in growing inorganically and expanding its international footprint.
Over the past 60 days, the Zacks Consensus Estimate for BFH’s 2023 earnings has been revised 19.92% upward.
Bread Financial, based in Columbus, OH, continues to benefit from data-driven marketing strategies. Solid receivables growth in Card Services should drive its top line. Acquisitions and divestitures will aid the company in growing inorganically and expanding its international footprint.
Over the past 60 days, the Zacks Consensus Estimate for BFH’s 2023 earnings has been revised 19.92% upward.